FindTrial
Sign In

Impact of TP53 and RB1 Co-mutations on the Clinical and Molecular Features of Breast Cancer: A Retrospective Observational Study

Impact of TP53 and RB1 Co-mutations on the Clinical and Molecular Features of Breast Cancer: A Retrospective Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105865
Enrollment
Unknown
Registered
2025-07-14
Start date
2025-07-15
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

TP53 and RB1 co-mutation group:None
RB1 single mutation group:None
TP53 and RB1 wild-type group:None
TP53 single mutation group:None

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed diagnosis of breast cancer; 2.No distant metastasis (M0); 3.Underwent radical surgery with R0 resection achieved; 4.Completed postoperative 1,021-gene panel next-generation sequencing (NGS) testing;

Exclusion criteria

Exclusion criteria: 1.Patients with incomplete clinical data or missing NGS testing results; 2.Patients with concurrent malignant tumors; 3.Patients with incomplete follow-up data or lost to follow-up;

Design outcomes

Primary

MeasureTime frame
Disease-free survival;—

Secondary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactXu Yan

Army Medical Center of PLA

xy931@163.com+86 15923100038

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026